HeraMED Limited (HMD)
CXA CXA Primary Summary
HeraMED Limited (HMD) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has HeraMED Limited ever had a stock split?
HeraMED Limited Profile
| Health Care Providers & Services Industry | Healthcare Sector | Ms. Anoushka Gungadin CEO | CXA Exchange | - ISIN |
| Israel Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
HeraMED Limited, established in 2011 and headquartered in Netanya, Israel, functions in the healthcare technology sector by specializing in the development, manufacture, and sale of fetal heartbeat monitors and additional pregnancy monitoring solutions designed principally for home use. This company offers its innovative products and services not only in its home country, Israel, but also in considerable markets such as Australia and Europe. HeraMED prides itself on its strategic collaboration with the prestigious Mayo Clinic, aimed at enhancing its HeraCARE pregnancy management platform, thus aligning its objectives toward advancements in remote maternity care technologies.
Products and Services
HeraBEAT - HeraBEAT is a state-of-the-art fetal heart rate monitor, devised with the convenience and reassurance of expectant mothers in mind. This device enables mothers-to-be to monitor their fetus' heartbeat from the comfort of their homes, promoting a sense of involvement and peace throughout their pregnancy journey.
HeraCARE - HeraCARE represents a comprehensive, cloud-based remote maternity care platform. It's designed to facilitate a deeper connection and seamless communication between expectant mothers and their healthcare providers. The platform's architecture supports the aggregation of vital health data, which can then be used to monitor, analyze, and act upon various health parameters during pregnancy, thereby contributing to enhanced prenatal care.
